Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)

Summary

Xanamem is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaCIDD Phase II study in MDD is to investigate the safety and efficacy of Xanamem™ in treating patients with cognitive and depressive symptoms. Trial participants will be randomized to either receive 10mg of Xanamem™ once daily or a Placebo at a 1:1 ratio in a double-blinded fashion.

Timeline

Start

2022-11-28

Primary completion

2024-07-01

Completion

2024-07-01

Drugs

Indications